Tadalafil (brand name Cialis � (EU, U.S., Switzerland), the manufacturer, Lilly Pharmaceuticals) is a powerful tool, and the treatment of erectile dysfunction.
Annex [edit]
Cialis is similar to sildenafil (used to treat pulmonary hypertension, pulmonary hypertension, PAH) and vardenafil for the enzyme phosphodiesterase 5 (PDE 5) inhibitors. PDE-5 is responsible for ensuring that an erection is reduced to prevent persistent erection of the cavernous tissue dies due to lack of circulation. By inhibiting PDE-5, arrived in a little sexual stimulation an erection that lasts longer. This is a PDE-5 inhibitors can not substitute for sexual stimulation. An erection does not affect the duration of the PDE-5 inhibitors. At the same time may occur depending on the formation of an erection and ejaculation than men.
Pharmacokinetics [Edit]
Tadalafil is 17.5 hours, much longer half-life of sildenafil (Viagra) and vardenafil. Even if the effect lasts from 4 to 6:00 hours of sildenafil and vardenafil from August to December, can be up to 36 hours for tadalafil. The effect is usually one, but it may take up to six hours before the effect is felt. Further integration should be carried out only after the complete cessation of activity, as this can lead to accumulation in the body and lead to undesirable and sometimes dangerous side effects.
Side effects
cialis has been used by about 15,000 men participating in clinical trials, and more than 8 million people worldwide (primarily in post-approval/post-marketing institutions). The most common side effects when using tadalafil side effects are headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition on the blood vessels to dilate (widen blood vessels) and usually disappear after a few hours. Back pain and muscle aches can occur 12 to 24 hours after taking the drug and the symptoms usually disappear within 48 hours.
In May 2005 the Food and Drug Administration in the U.S. have shown that cialis (along with other PDE5 inhibitors) was associated with visual impairment related to NAION (not arteritic anterior ischemic optic neuropathy) in certain patients taking these drugs outside of clinical trials . Most but not all of these patients, risk factors, underlying anatomic or vascular development of NAION associated with the use of PDE-5, including a record low speed ratio ("crowded disc"), 50 years, diabetes mellitus, hypertension, coronary heart disease, hyperlipidemia and smoking. Given the small number of NAION events compared with the use of PDE-5 (less than 1 in 1 million), a large number of users of PDE5 inhibitors million) and the fact that such an event occurs in a similar population not taking these drugs, FDA has concluded that they could not establish cause and effect. However, the labels of all three PDE5 inhibitors was changed to warn doctors of possible associations.
In October 2007, the FDA announced that labeling for all PDE5 inhibitors, including cialis, prominently the potential risk of sudden hearing loss due to post-marketing cases of deafness associated with reporting "The use of inhibitors PDE5.6
Annex [edit]
Cialis is similar to sildenafil (used to treat pulmonary hypertension, pulmonary hypertension, PAH) and vardenafil for the enzyme phosphodiesterase 5 (PDE 5) inhibitors. PDE-5 is responsible for ensuring that an erection is reduced to prevent persistent erection of the cavernous tissue dies due to lack of circulation. By inhibiting PDE-5, arrived in a little sexual stimulation an erection that lasts longer. This is a PDE-5 inhibitors can not substitute for sexual stimulation. An erection does not affect the duration of the PDE-5 inhibitors. At the same time may occur depending on the formation of an erection and ejaculation than men.
Pharmacokinetics [Edit]
Tadalafil is 17.5 hours, much longer half-life of sildenafil (Viagra) and vardenafil. Even if the effect lasts from 4 to 6:00 hours of sildenafil and vardenafil from August to December, can be up to 36 hours for tadalafil. The effect is usually one, but it may take up to six hours before the effect is felt. Further integration should be carried out only after the complete cessation of activity, as this can lead to accumulation in the body and lead to undesirable and sometimes dangerous side effects.
Side effects
cialis has been used by about 15,000 men participating in clinical trials, and more than 8 million people worldwide (primarily in post-approval/post-marketing institutions). The most common side effects when using tadalafil side effects are headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition on the blood vessels to dilate (widen blood vessels) and usually disappear after a few hours. Back pain and muscle aches can occur 12 to 24 hours after taking the drug and the symptoms usually disappear within 48 hours.
In May 2005 the Food and Drug Administration in the U.S. have shown that cialis (along with other PDE5 inhibitors) was associated with visual impairment related to NAION (not arteritic anterior ischemic optic neuropathy) in certain patients taking these drugs outside of clinical trials . Most but not all of these patients, risk factors, underlying anatomic or vascular development of NAION associated with the use of PDE-5, including a record low speed ratio ("crowded disc"), 50 years, diabetes mellitus, hypertension, coronary heart disease, hyperlipidemia and smoking. Given the small number of NAION events compared with the use of PDE-5 (less than 1 in 1 million), a large number of users of PDE5 inhibitors million) and the fact that such an event occurs in a similar population not taking these drugs, FDA has concluded that they could not establish cause and effect. However, the labels of all three PDE5 inhibitors was changed to warn doctors of possible associations.
In October 2007, the FDA announced that labeling for all PDE5 inhibitors, including cialis, prominently the potential risk of sudden hearing loss due to post-marketing cases of deafness associated with reporting "The use of inhibitors PDE5.6